Skip to the content
Know your tech before you buy it. Makers: get listed from $49/mo

AlgoraeOS

algoraepharma.com

5.5 Club score Visit algoraepharma.com

What the maker publishes

Benchmarking
The company says AOS2 outperformed representative state-of-the-art models in published benchmarks. source
Closed-loop design
Discovery and pre-clinical development data continuously feed back to strengthen the platform's predictive capability. source
Current candidates
The site identifies AI-116 and AI-168 as priority licensing candidates. source
Data inputs
The platform connects pre-clinical, clinical, chemical and biological data to generate drug-combination candidates. source
Dose-response models
AlgoraeOS models dose-response surfaces using Bliss, Loewe, HSA and ZIP. source
Headquarters
Melbourne, Victoria, Australia source
Headquarters
Algorae lists its address in Melbourne, Victoria, Australia. source
Independent validation
Independent wet-lab validation at Peter MacCallum Cancer Centre tested 21 drug-drug targets across four cancer cell lines, generating approximately 10,000 data points. source
Intellectual property
Algorae states that the platform's intellectual property is 100% owned by the company. source
Licensing and co-development
Validated candidates are available for out-licensing and co-development with pharmaceutical and biotech partners. source
Prediction scale
The platform has generated 500,000 drug-cell line predictions across 3,000+ drugs and 170 cancer cell lines. source
Purpose
AlgoraeOS is an AI-powered drug discovery platform that generates drug-combination candidates for licensing and co-development. source
Research infrastructure
The UNSW Data Science Hub provides data analysis tools and access to high-performance computing infrastructure for the collaboration. source
Research partners
Named research partners are UNSW AI Institute, CSIRO/Data61 and Peter MacCallum Cancer Centre. source
Training data
AlgoraeOS was trained on more than 5.5 million unique inhibition records, approximately 11 million with augmentation. source

Checked against the maker's pages on 14 Nov 2026.